Qualigen Therapeutics Inc
QLGN3.210USD
0.000
Close 12/19, 16:00（ET）Quotes delayed by 15 min
9.81MMarket Cap
LossP/E TTM
More Details of Qualigen Therapeutics Inc Company
Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.
Qualigen Therapeutics Inc Info
Ticker SymbolQLGN
Company nameAixcrypto Holdings Inc
IPO dateJun 24, 2015
CEOWang (Jiawei)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endJun 24
Address5857 Owens Avenue
CityCARLSBAD
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code92008
Phone17604528111
Websitehttp://aixcrypto.ai/
Ticker SymbolQLGN
IPO dateJun 24, 2015
CEOWang (Jiawei)
Company Executives of Qualigen Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin Chen
Mr. Kevin Chen
Independent Director
Independent Director
--
--
Mr. Jay (Jie) Sheng
Mr. Jay (Jie) Sheng
Chairman of the Board
Chairman of the Board
--
--
Mr. Chad Chen
Mr. Chad Chen
Director
Director
--
--
Mr. Jiawei (Jerry) Wang
Mr. Jiawei (Jerry) Wang
Co-Chief Executive Officer
Co-Chief Executive Officer
--
--
Mr. Koti Meka
Mr. Koti Meka
Chief Financial Officer, Executive Director
Chief Financial Officer, Executive Director
--
--
Mr. Campbell Becher
Mr. Campbell Becher
President
President
--
--
Mr. Kevin Richardson, II
Mr. Kevin Richardson, II
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Kevin Chen
Mr. Kevin Chen
Independent Director
Independent Director
--
--
Mr. Jay (Jie) Sheng
Mr. Jay (Jie) Sheng
Chairman of the Board
Chairman of the Board
--
--
Mr. Chad Chen
Mr. Chad Chen
Director
Director
--
--
Mr. Jiawei (Jerry) Wang
Mr. Jiawei (Jerry) Wang
Co-Chief Executive Officer
Co-Chief Executive Officer
--
--
Mr. Koti Meka
Mr. Koti Meka
Chief Financial Officer, Executive Director
Chief Financial Officer, Executive Director
--
--
Mr. Campbell Becher
Mr. Campbell Becher
President
President
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 18
Updated: Thu, Dec 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Faraday Future Intelligent Electric Inc
17.41%
Alpha Capital Aktiengesellschaft
2.18%
Jia (Yueting)
0.47%
Cubist Systematic Strategies, LLC
0.40%
Geode Capital Management, L.L.C.
0.07%
Other
79.48%
Shareholders
Shareholders
Proportion
Faraday Future Intelligent Electric Inc
17.41%
Alpha Capital Aktiengesellschaft
2.18%
Jia (Yueting)
0.47%
Cubist Systematic Strategies, LLC
0.40%
Geode Capital Management, L.L.C.
0.07%
Other
79.48%
Shareholder Types
Shareholders
Proportion
Corporation
17.41%
Holding Company
2.18%
Individual Investor
0.49%
Hedge Fund
0.40%
Investment Advisor/Hedge Fund
0.07%
Investment Advisor
0.07%
Other
79.38%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
34
8.02K
0.39%
-33.36K
2025Q2
35
29.16K
1.78%
-14.08K
2025Q1
34
36.38K
4.94%
+694.00
2024Q4
32
38.55K
5.23%
+8.85K
2024Q3
42
40.42K
6.16%
+16.65K
2024Q2
45
22.38K
15.60%
+3.43K
2024Q1
46
20.13K
15.96%
+3.40K
2023Q4
48
14.90K
14.56%
-1.62K
2023Q3
55
14.26K
14.11%
-5.84K
2023Q2
57
13.80K
13.70%
-8.07K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Alpha Capital Aktiengesellschaft
36.43K
1.79%
+9.13K
+33.46%
Jul 21, 2025
Geode Capital Management, L.L.C.
5.26K
0.26%
--
--
Aug 31, 2025
BlackRock Institutional Trust Company, N.A.
511.00
0.03%
--
--
Jun 30, 2025
Tower Research Capital LLC
1.19K
0.06%
+814.00
+217.65%
Jun 30, 2025
Harbour Investments, Inc
325.00
0.02%
+325.00
--
Jun 30, 2025
View more
Related ETFs
Updated: Tue, Dec 2
Updated: Tue, Dec 2
Name
Proportion
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Nov 01, 2024
Merger
50→1
Nov 01, 2024
Merger
50→1
Nov 01, 2024
Merger
50→1
Nov 01, 2024
Merger
50→1
Nov 22, 2022
Merger
10→1
Nov 22, 2022
Merger
10→1
Date
Type
Ratio
Nov 01, 2024
Merger
50→1
Nov 01, 2024
Merger
50→1
Nov 01, 2024
Merger
50→1
Nov 01, 2024
Merger
50→1
Nov 22, 2022
Merger
10→1
Nov 22, 2022
Merger
10→1
Nov 22, 2022
Merger
10→1
Nov 22, 2022
Merger
10→1
May 22, 2020
Merger
25→1
May 22, 2020
Merger
25→1
View more
FAQs
Who are the top five shareholders of Qualigen Therapeutics Inc?
The top five shareholders of Qualigen Therapeutics Inc are:
Alpha Capital Aktiengesellschaft holds 36.43K shares, accounting for 1.79% of the total shares.
Geode Capital Management, L.L.C. holds 5.26K shares, accounting for 0.26% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 511.00 shares, accounting for 0.03% of the total shares.
Tower Research Capital LLC holds 1.19K shares, accounting for 0.06% of the total shares.
Harbour Investments, Inc holds 325.00 shares, accounting for 0.02% of the total shares.
Alpha Capital Aktiengesellschaft holds 36.43K shares, accounting for 1.79% of the total shares.
Geode Capital Management, L.L.C. holds 5.26K shares, accounting for 0.26% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 511.00 shares, accounting for 0.03% of the total shares.
Tower Research Capital LLC holds 1.19K shares, accounting for 0.06% of the total shares.
Harbour Investments, Inc holds 325.00 shares, accounting for 0.02% of the total shares.
What are the top three shareholder types of Qualigen Therapeutics Inc?
The top three shareholder types of Qualigen Therapeutics Inc are:
Faraday Future Intelligent Electric Inc
Alpha Capital Aktiengesellschaft
Jia (Yueting)
Faraday Future Intelligent Electric Inc
Alpha Capital Aktiengesellschaft
Jia (Yueting)
How many institutions hold shares of Qualigen Therapeutics Inc (QLGN)?
As of 2025Q3, 34 institutions hold shares of Qualigen Therapeutics Inc, with a combined market value of approximately 8.02K, accounting for 0.39% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -1.39%.
What is the biggest source of revenue for Qualigen Therapeutics Inc?
In --, the -- business generated the highest revenue for Qualigen Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
